Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.
Nom du journal : Nat Commun
Année : 2023
Volume : 14
Page de départ : 7018
